Iwamoto Aya, Summers Karen M, Sparks Amy, Mancuso Abigail C
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
F S Rep. 2024 Jun 19;5(3):263-271. doi: 10.1016/j.xfre.2024.06.003. eCollection 2024 Sep.
To compare cumulative live birth rate (CLBR) and cost-effectiveness of intracytoplasmic sperm injection (ICSI) vs. conventional in vitro fertilization (cIVF).
Retrospective cohort study of cycles reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.
Society for Assisted Reproductive Technology (SART) member IVF clinics in the United States.
Patients with unexplained infertility who underwent first autologous retrieval cycles between January 2017 and December 2019 with linked fresh and frozen embryo transfers through December 2021.
ICSI vs. cIVF.
The primary outcome was CLBR, defined as ≤1 live birth from a retrieval cycle and all linked embryo transfers. Secondary outcomes included two pronuclear (2PN) per oocyte retrieved, miscarriage rate, and total number of transferred or frozen embryos per 2PN. Subsamples with and without preimplantation genetic testing for aneuploidy (PGT-A) were analyzed. Outcomes were adjusted for age, body mass index, number of oocytes retrieved, length of follow-up, and clinic ICSI use rate.
A total of 18,805 patients with unexplained infertility were included. No difference in CLBR was found among cycles without genetic testing (54.4% ICSI vs. 57.5% cIVF) and with PGT-A (47.6% ICSI vs. 51.8% cIVF). Intracytoplasmic sperm injection cycles without genetic testing had a higher miscarriage rate (16.4% vs. 14.4%) but no difference was seen in cycles with PGT-A (13.9% ICSI vs. 13.2% cIVF). Intracytoplasmic sperm injection cycles had a significantly lower ratio of 2PN per oocyte retrieved without genetic testing (59.7% vs. 60.9%) and with PGT-A (63.3% vs. 65.8%). The ratio of embryos transferred or frozen per 2PN was not significantly different in cycles without genetic testing (49.4% vs. 49.6%) or with PGT-A (54.2% vs. 55.2%). Total fertilization failure occurred in 216 patients (4%) who underwent cIVF and in 153 patients (1.1%) who used ICSI.Compared with cIVF alone, an estimated additional $11,011,500 was charged to patients for ICSI without genetic testing and $9,010,500 was charged to patients for ICSI with PGT-A over 2 years by Society for Assisted Reproductive Technology clinics. On the basis of total fertilization failure rates, 35 patients would require treatment with routine ICSI to avoid a single cycle of total fertilization failure with cIVF.
Routine use of ICSI in unexplained infertility is not warranted due to the additional cost and lack of CLBR benefit.
比较卵胞浆内单精子注射(ICSI)与传统体外受精(cIVF)的累积活产率(CLBR)和成本效益。
对向辅助生殖技术协会诊所结局报告系统报告的周期进行回顾性队列研究。
美国辅助生殖技术协会(SART)成员体外受精诊所。
2017年1月至2019年12月期间接受首次自体取卵周期且在2021年12月前有新鲜和冷冻胚胎移植关联的不明原因不孕症患者。
ICSI与cIVF。
主要结局为CLBR,定义为一次取卵周期及所有关联胚胎移植后≤1次活产。次要结局包括每个回收卵母细胞的双原核(2PN)、流产率以及每2PN移植或冷冻胚胎的总数。对进行和未进行非整倍体植入前基因检测(PGT-A)的子样本进行分析。结局根据年龄、体重指数、回收卵母细胞数量、随访时间和诊所ICSI使用率进行调整。
共纳入18805例不明原因不孕症患者。在未进行基因检测的周期中(ICSI为54.4%,cIVF为57.5%)和进行PGT-A的周期中(ICSI为47.6%,cIVF为51.8%),CLBR未发现差异。未进行基因检测的ICSI周期流产率较高(16.4%对14.4%),但在进行PGT-A的周期中未发现差异(ICSI为13.9%,cIVF为13.2%)。未进行基因检测的ICSI周期每个回收卵母细胞的2PN比例显著较低(59.7%对60.9%),进行PGT-A的周期中也是如此(63.3%对65.8%)。未进行基因检测的周期(49.4%对49.6%)或进行PGT-A的周期(54.2%对55.2%)中,每2PN移植或冷冻胚胎的比例无显著差异。216例接受cIVF的患者(4%)和153例使用ICSI的患者(1.1%)发生了完全受精失败。与单独使用cIVF相比,辅助生殖技术协会诊所对未进行基因检测的ICSI患者在2年内额外收取11,011,500美元,对进行PGT-A的ICSI患者额外收取9,010,500美元。根据完全受精失败率,35例患者需要接受常规ICSI治疗以避免cIVF出现一次完全受精失败周期。
由于额外成本和缺乏CLBR益处,不明原因不孕症中不建议常规使用ICSI。